These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 32424162)

  • 1. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.
    Gupta V; Salim S; Hmila I; Vaikath NN; Sudhakaran IP; Ghanem SS; Majbour NK; Abdulla SA; Emara MM; Abdesselem HB; Lukacsovich T; Erskine D; El-Agnaf OMA
    Sci Rep; 2020 May; 10(1):8137. PubMed ID: 32424162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity.
    Ghanem SS; Majbour NK; Vaikath NN; Ardah MT; Erskine D; Jensen NM; Fayyad M; Sudhakaran IP; Vasili E; Melachroinou K; Abdi IY; Poggiolini I; Santos P; Dorn A; Carloni P; Vekrellis K; Attems J; McKeith I; Outeiro TF; Jensen PH; El-Agnaf OMA
    Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2109617119. PubMed ID: 35353605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression, purification and characterization of α-synuclein fibrillar specific scFv from inclusion bodies.
    Gupta V; Sudhakaran IP; Islam Z; Vaikath NN; Hmila I; Lukacsovich T; Kolatkar PR; El-Agnaf OMA
    PLoS One; 2020; 15(11):e0241773. PubMed ID: 33156828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
    Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
    Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of α-Synuclein Seeding-Dependent Aggregation by ssDNA Aptamers Specific to C-Terminally Truncated α-Synuclein Fibrils.
    Hmila I; Sudhakaran IP; Ghanem SS; Vaikath NN; Poggiolini I; Abdesselem H; El-Agnaf OMA
    ACS Chem Neurosci; 2022 Dec; 13(23):3330-3341. PubMed ID: 36348612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy.
    Nimmo JT; Verma A; Dodart JC; Wang CY; Savistchenko J; Melki R; Carare RO; Nicoll JAR
    Alzheimers Res Ther; 2020 Nov; 12(1):159. PubMed ID: 33256825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology.
    Kumar ST; Jagannath S; Francois C; Vanderstichele H; Stoops E; Lashuel HA
    Neurobiol Dis; 2020 Dec; 146():105086. PubMed ID: 32971232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity in α-synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease.
    Vaikath NN; Erskine D; Morris CM; Majbour NK; Vekrellis K; Li JY; El-Agnaf OMA
    Neuropathol Appl Neurobiol; 2019 Oct; 45(6):597-608. PubMed ID: 30422353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligodendrocytes Prune Axons Containing α-Synuclein Aggregates In Vivo: Lewy Neurites as Precursors of Glial Cytoplasmic Inclusions in Multiple System Atrophy?
    De Nuccio F; Kashyrina M; Serinelli F; Laferrière F; Lofrumento DD; De Giorgi F; Ichas F
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
    Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
    J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FKBP12-immunopositive inclusions in patients with α-synucleinopathies.
    Honjo Y; Ayaki T; Horibe T; Ito H; Takahashi R; Kawakami K
    Brain Res; 2018 Feb; 1680():39-45. PubMed ID: 29246765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration.
    Peelaerts W; Bousset L; Van der Perren A; Moskalyuk A; Pulizzi R; Giugliano M; Van den Haute C; Melki R; Baekelandt V
    Nature; 2015 Jun; 522(7556):340-4. PubMed ID: 26061766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.
    Dufty BM; Warner LR; Hou ST; Jiang SX; Gomez-Isla T; Leenhouts KM; Oxford JT; Feany MB; Masliah E; Rohn TT
    Am J Pathol; 2007 May; 170(5):1725-38. PubMed ID: 17456777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
    Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of α-Synuclein by Oligodendrocytes in Transgenic Mice Does Not Recapitulate the Fibrillar Aggregation Seen in Multiple System Atrophy.
    Laferrière F; He X; Zinghirino F; Doudnikoff E; Faggiani E; Meissner WG; Bezard E; De Giorgi F; Ichas F
    Cells; 2020 Oct; 9(11):. PubMed ID: 33138150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylated α-synuclein in skin Schwann cells: a new biomarker for multiple system atrophy.
    Donadio V; Incensi A; Rizzo G; Westermark GT; Devigili G; De Micco R; Tessitore A; Nyholm D; Parisini S; Nyman D; Tedeschi G; Eleopra R; Ingelsson M; Liguori R
    Brain; 2023 Mar; 146(3):1065-1074. PubMed ID: 35552610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening.
    Henderson-Smith A; Chow D; Meechoovet B; Aziz M; Jacobson SA; Shill HA; Sabbagh MN; Caviness JN; Adler CH; Driver-Dunckley ED; Beach TG; Yin H; Dunckley T
    PLoS One; 2013; 8(10):e77711. PubMed ID: 24204929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropathology and molecular diagnosis of Synucleinopathies.
    Koga S; Sekiya H; Kondru N; Ross OA; Dickson DW
    Mol Neurodegener; 2021 Dec; 16(1):83. PubMed ID: 34922583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aptamer binding footprints discriminate α-synuclein fibrillar polymorphs from different synucleinopathies.
    Bouvier-Müller A; Fourmy D; Fenyi A; Bousset L; Melki R; Ducongé F
    Nucleic Acids Res; 2024 Aug; 52(14):8072-8085. PubMed ID: 38917326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies.
    Paleologou KE; Kragh CL; Mann DM; Salem SA; Al-Shami R; Allsop D; Hassan AH; Jensen PH; El-Agnaf OM
    Brain; 2009 Apr; 132(Pt 4):1093-101. PubMed ID: 19155272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.